OBJECTIVE: Glioma-associated stem cells (GASCs) have been indicated as possible players in supporting growth and recurrence in glioblastoma. However, their role in modulating immune response in the peritumoral area has not yet been described. In this study, the authors aimed to investigate programmed death-ligand 1 (PD-L1) differential expression at the protein level in GASCs derived from different tumor areas (core, periphery, and surrounding healthy brain). METHODS: Tumor tissue samples were collected from patients who underwent surgery for a histopathologically confirmed diagnosis of glioblastoma. Sampling sites were confirmed via neuronavigation and categorized on 5-aminolevulinic acid (5-ALA) fluorescence as bright (ALA+), pale (ALA PA...
Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) have been highly succe...
Copyright © 2014 Davide Schiffer et al.This is an open access article distributed under the Creative...
Glioblastoma is a deadly disease, with a mean overall survival of less than 2 years from diagnosis. ...
BACKGROUND: Immune checkpoint inhibitors targeting programmed cell death 1 (PD1) or its ligand (PD-L...
BACKGROUND Immune checkpoint inhibitors targeting programmed cell death 1 (PD1) or its ligand (PD-L...
Glioblastoma (GB), the most aggressive malignant glioma, is made up of a large percentage of glioma-...
Glioblastoma (GB), the most aggressive malignant glioma, is made up of a large percentage of glioma-...
Glioblastoma (GB), the most aggressive malignant glioma, is made up of a large percentage of glioma-...
Programmed death 1 (PD-1, CD279) and programmed death ligand 1 (PD-L1, CD274) are involved in genera...
Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor. In general, tumor growth r...
With the advent of immunotherapies, the field of cancer therapy has been revived with new hope, espe...
With the advent of immunotherapies, the field of cancer therapy has been revived with new hope, espe...
Glioblastoma (GB), the most aggressive malignant glioma, is made up of a large percentage of glioma-...
Binding of programmed death ligand-1 (PD-L1) to programmed cell death protein-1 (PD1) leads to cance...
BACKGROUND: Characterizing expression profiles of different immune checkpoint molecules are promisin...
Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) have been highly succe...
Copyright © 2014 Davide Schiffer et al.This is an open access article distributed under the Creative...
Glioblastoma is a deadly disease, with a mean overall survival of less than 2 years from diagnosis. ...
BACKGROUND: Immune checkpoint inhibitors targeting programmed cell death 1 (PD1) or its ligand (PD-L...
BACKGROUND Immune checkpoint inhibitors targeting programmed cell death 1 (PD1) or its ligand (PD-L...
Glioblastoma (GB), the most aggressive malignant glioma, is made up of a large percentage of glioma-...
Glioblastoma (GB), the most aggressive malignant glioma, is made up of a large percentage of glioma-...
Glioblastoma (GB), the most aggressive malignant glioma, is made up of a large percentage of glioma-...
Programmed death 1 (PD-1, CD279) and programmed death ligand 1 (PD-L1, CD274) are involved in genera...
Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor. In general, tumor growth r...
With the advent of immunotherapies, the field of cancer therapy has been revived with new hope, espe...
With the advent of immunotherapies, the field of cancer therapy has been revived with new hope, espe...
Glioblastoma (GB), the most aggressive malignant glioma, is made up of a large percentage of glioma-...
Binding of programmed death ligand-1 (PD-L1) to programmed cell death protein-1 (PD1) leads to cance...
BACKGROUND: Characterizing expression profiles of different immune checkpoint molecules are promisin...
Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) have been highly succe...
Copyright © 2014 Davide Schiffer et al.This is an open access article distributed under the Creative...
Glioblastoma is a deadly disease, with a mean overall survival of less than 2 years from diagnosis. ...